Anil Matai, Vijender Singh join Jashvik Capital

Jashvik Capital, an India-focused growth private equity firm, has hired Anil Matai and Vijender Singh as Operating Partners.

Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr. Lal’s Pathlabs, where Vijender helped scale both these companies under private equity ownership.

Anil Matai was most recently Managing Director of Zydus Healthcare and CEO of Novartis Pharma India. Zydus Healthcare is India’s top 5 domestic formulations company. Previously, he also held leadership positions at GlaxoSmithKline India.

“Anil and Vijender have deep networks in healthcare/pharma and various consumption-linked sectors. They have decades long experience in building best-in-class organizations, scaling them and establishing commanding market leadership positions," said Naresh Patwari, Founder of Jashvik Capital.

Jashvik Capital is a SEBI registered Category II Alternative Investment Fund. The firm will invest alongside founders of profitable growth businesses in healthcare and consumption-linked sectors.

"As India aims to grow from a $3 tn to a $30 tn economy, healthcare and consumer sectors will account for a disproportionate share of that growth and high-quality, profitable growth businesses in the mid-
market will be fundamental to delivering on this opportunity. We want to partner with the founders
of these businesses and help them realize their vision and strategies," said Vijender Singh.

“At Jashvik Capital, we want to partner with exceptional founders and management teams and support them as they scale their businesses in an accelerated, profitable and sustainable manner,” said Anil Matai.

Jashvik Capital, founded by Naresh Patwari - former partner at TA Associates, plans to raise about $350 million in its recently launched debut fund.

The healthcare- and consumer-focused fund is expected to close within 12 months.